Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Regenerative cellular therapies for neurologic diseases.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Copaxone
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study.
Rituximab (marketed as Rituxan), Information
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Product Portfolio, Meda
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
Multiple sclerosis: association with HL-A3.
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Long-term effectiveness of glatiramer acetate in clinical practice conditions.
[Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine].
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.

Pages